Cannabis & PTSD — What the Evidence Actually Shows
Veterans with PTSD deserve honest information about cannabis. Not false hope. Not dismissive skepticism. This page summarizes every major RCT, systematic review, and observational study relevant to cannabis and veteran PTSD as of April 2026.
The Honest Summary
The only completed RCT of smoked cannabis for veteran PTSD found no statistically significant advantage over placebo. Observational studies suggest benefit but have severe limitations. The biology provides plausible mechanism. Research suggests cannabis might help some veterans; research does not yet prove it is an effective PTSD treatment. The VA/DoD 2023 Clinical Practice Guideline strongly recommends against cannabis for PTSD.
The Only Completed RCT: Bonn-Miller et al. 2021 (MAPS/Sisley)
The most rigorous study of smoked cannabis for PTSD in veterans was the MAPS/Sisley Phase 2 trial (MJP1), published in 2021.
This FDA-approved, double-blind, placebo-controlled, crossover trial randomized 80 veterans to four arms:
- High THC (~12% THC)
- High CBD (~11% CBD)
- THC+CBD (~8% THC, ~8% CBD)
- Placebo
Treatment lasted 3 weeks per stage with self-administration of up to 1.8 g/day. The primary endpoint was change on the CAPS-5 (Clinician-Administered PTSD Scale for DSM-5).
Key result: No statistically significant difference between any active cannabis group and placebo on the primary CAPS-5 endpoint. All four groups — including placebo — showed significant improvement from baseline. The high THC group had a 100% blind-break rate (every participant correctly identified they were receiving active cannabis), fundamentally compromising the double-blind design.
The study did demonstrate that short-term cannabis use was safe and well-tolerated, with only mild-to-moderate adverse events. But it did not prove efficacy.
The Potency Caveat
All cannabis was supplied by NIDA's sole licensed producer at the time (University of Mississippi), with THC potency of 9–12% — approximately half the potency of products available in state dispensaries (averaging 15–22% THC). PI Dr. Sue Sisley and MAPS founder Rick Doblin both argued this potency gap may explain the discrepancy between anecdotal reports and trial results. This is the single most important limitation of the 2021 findings.
The Next Trial: MJP2
A second MAPS Phase 2 trial (MJP2) received FDA clearance to proceed in November 2024 after three years of partial clinical holds. It targets 320 veterans with moderate-to-severe PTSD, uses cannabis matching commercial potency, and employs a parallel (not crossover) design. Funded by a $12.9 million Michigan grant. First participant treatment is projected for early 2026. No results are available as of April 2026. There is no "Phase 3" cannabis trial — the MAPS Phase 3 trial was for MDMA, not cannabis.
Observational Studies: Suggestive but Severely Limited
Greer et al. found a >75% reduction in CAPS scores when patients compared symptoms during cannabis use versus without. This finding is frequently cited but must be understood in context: screening criteria required patients to already report significant relief from cannabis. The sample was pre-selected to include only responders. No control group, no blinding, retrospective recall.
Open-label pilot of 5 mg oral THC twice daily in 10 patients with chronic PTSD (co-authored by Raphael Mechoulam, the discoverer of the endocannabinoid system). Showed significant improvements in sleep quality, nightmare frequency, and hyperarousal symptoms.
Systematic Reviews: Sobering Picture
NASEM 2017
The National Academies of Sciences, Engineering, and Medicine (NASEM) 2017 report classified the evidence for cannabis and PTSD as "limited evidence" — the third tier of a five-tier hierarchy. The report also noted "limited evidence of an association between smoked Cannabis and increased symptoms in patients with PTSD."
Rodas et al. 2024
Reviewed 14 studies. Of 10 examining overall PTSD symptoms in non-CUD samples, 5 suggested benefits and 5 suggested no effect or worsening. All 3 studies in comorbid CUD samples reported worsening symptoms. Conclusion: "Did not find major benefits of cannabinoids in improving overall PTSD symptoms."
Wilson et al. 2026
The largest meta-analysis to date — 54 RCTs across 45 years — found no effective evidence for cannabis treating anxiety, depression, or PTSD.
The Endocannabinoid System Provides Biological Plausibility
There is a compelling mechanistic rationale for why veterans with PTSD might seek cannabis.
PET scanning in 60 participants (25 with PTSD) found that PTSD patients had 19.5% higher brain CB1 receptor availability and 53–58% lower anandamide levels compared to healthy controls. These three biomarkers correctly classified approximately 85% of PTSD cases.
Preclinical research by Marsicano et al. (2002, Nature) demonstrated that the endocannabinoid system is critical for fear extinction — the brain's ability to unlearn fear responses, which is impaired in PTSD. However, a 2025 RCT (Mayo et al., Neuropsychopharmacology, 50:1564-1572) testing a FAAH inhibitor to raise anandamide levels in 100 PTSD patients found no effect on PTSD outcomes despite confirmed anandamide elevation.
The biology provides a plausible rationale for self-medication. It does not prove clinical efficacy.
The Extinction Learning Concern
Emerging evidence suggests cannabis may impair extinction learning, potentially interfering with the gold-standard trauma-focused psychotherapies (prolonged exposure, cognitive processing therapy) that have strong evidence for PTSD. This is perhaps the most concerning finding in the literature: cannabis may not only fail to treat PTSD directly but may also compromise treatments that do work.
VA/DoD Clinical Practice Guideline
What This Means for Veterans with PTSD
- If you are considering cannabis for PTSD, you should understand that the evidence does not currently support it as an effective treatment. This is an honest assessment, not a recommendation for or against your personal choice.
- Evidence-based PTSD treatments exist and work. Prolonged exposure (PE), cognitive processing therapy (CPT), and EMDR have strong evidence. SSRI/SNRI medications help many veterans. VA treatment options.
- VA will treat you whether or not you use cannabis. Abstinence is not required before PTSD treatment.
- If you use cannabis and have PTSD, tell your VA provider. They can help you safely manage medications and weigh treatment options. Honest disclosure.
- Watch for cannabis use disorder. 72% of veterans with CUD have comorbid PTSD. CUD can worsen PTSD symptoms and complicate treatment. CUD in veterans.